ASTEC/EN.5 Study Group, Blake, P., Swart, A.M., Orton, J., Kitchener, H., Whelan, T., Lukka, H., et al. (2009) Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer (MRC ASTEC and NCIC-CTG EN.5 Randomised Trials): Pooled Trial Results, Systematic Review, and Meta-Analysis. Lancet, 373, 137-146. http://dx.doi.org/10.1016/S0140-6736(08)61767-5

has been cited by the following article:

• TITLE: Adjuvant External Beam Radiotherapy ± Brachytherapy in Endometrial Cancer: A Retrospective Study from Faculty of Medicine, Chiang Mai University

  AUTHORS: Ekkasit Tharavichitkul, Sukon Prasitwattanaseree, Patrinee Traisathit, Cholthicha Thipmate, Somvilai Chakrabandhu, Pitchayaponne Klunklin, Wimrak Onchan, Razvan M. Galalae, Imjai Chitapanarux

  KEYWORDS: Endometrial Cancer, Adjuvant Treatment, External Beam Radiotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.2, January 29, 2015

  ABSTRACT: Purpose: To report the retrospective study of external beam radiotherapy (EBRT) ± intravaginal brachytherapy (IVBT) as adjuvant treatment for endometrial cancer. Materials and Methods: From 2001-2009, 152 patients received complete surgical staging for endometrial carcinoma and were designed by a multidisciplinary team to receive EBRT ± IVBT. The treatment results and late toxicities were evaluated and recorded. Results: At the median follow-up time of 43 months, the disease-free survival, metastasis-free survival and overall survival rates were 96.9%, 96.9% and 96.9%, respectively. Stage and age showed the statistical significance with the p-value of less than 0.001. From five to ten percent of patients developed Grades 1-2 late gastrointestinal and genitourinary toxicities, respectively. Conclusion: The using of adjuvant EBRT ± IVBT for endometrialcarcinoma yielded treatment results and acceptable toxicities.